Drugs & Targets Nuvalent submits NDA to FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC April 10, 2026Vol.52 No.14
News Analysis HHS presents new protein-forward dietary guidelines, turning the food pyramid upside downThe Kennedy guidelines are mum on cancer risks associated with red meat and alcohol April 03, 2026Vol.52 No.13By Claire Marie Porter
FreeGuest Editorial FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters mostDraft guidance consolidates trial design updates for developers April 03, 2026Vol.52 No.13By Nicholas Richardson
Drugs & Targets FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients April 03, 2026Vol.52 No.13
Drugs & Targets FDA grants priority review to Elevar Therapeutics’s lirafugratinib as second-line cholangiocarcinoma treatment April 03, 2026Vol.52 No.13
Cancer Policy FDA issues warning letter to ImmunityBio over misleading claims about cancer drug March 27, 2026Vol.52 No.12By Claire Marie Porter
Cancer Policy FDA withdraws proposed rule that would have banned minors from using tanning beds March 27, 2026Vol.52 No.12By Claire Marie Porter
Cancer Policy FDA issues draft guidance to reduce animal testing March 27, 2026Vol.52 No.12By Claire Marie Porter
Drugs & Targets FDA and EC approve Opdivo IO combinations in classical Hodgkin Lymphoma March 27, 2026Vol.52 No.12
